Clinical Trials
45 trialsA Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Takeda
RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease
European Organisation for Research and Treatment of Cancer - EORTC
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma
University College, London
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Eastern Cooperative Oncology Group
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
SWOG Cancer Research Network
Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members
National Institute of Allergy and Infectious Diseases (NIAID)
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
M.D. Anderson Cancer Center
Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma
Stanford University
Combination Chemotherapy in Treating Patients With Lymphoma
M.D. Anderson Cancer Center
Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma
Lymphoma Study Association
Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma
Stanford University
GAINED
The Lymphoma Academic Research Organisation
Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years
Newcastle-upon-Tyne Hospitals NHS Trust
Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma
French Innovative Leukemia Organisation
A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma
Seagen Inc.
Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease
Children's Oncology Group
Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease
Children's Oncology Group
Combination Chemotherapy Given With Radiation Therapy or Radiation Therapy Alone in Treating Patients With Early-Stage Hodgkin's Disease
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Hodgkin's Disease and HIV Infection
National Cancer Institute (NCI)
Rituximab Plus Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Combination Chemotherapy Plus Filgrastim in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma
National Cancer Institute (NCI)
Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease
Children's Oncology Group
Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma
National Cancer Institute (NCI)
Radiation Therapy or Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma
National Cancer Institute (NCI)
Rituximab and ABVD for Hodgkin's Patients
M.D. Anderson Cancer Center
Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease
National Cancer Institute (NCI)
Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease
M.D. Anderson Cancer Center
SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma
SWOG Cancer Research Network
SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant
SWOG Cancer Research Network
S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease
SWOG Cancer Research Network
Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma
M.D. Anderson Cancer Center
Bleomycin in Treating Patients With Non-Hodgkin's Lymphoma
Case Comprehensive Cancer Center
Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)